Fennec Pharmaceuticals (FENC) Net Margin (2020 - 2026)

Fennec Pharmaceuticals (FENC) has 4 years of Net Margin data on file, last reported at 34.22% in Q4 2025.

• Quarterly Net Margin fell 1841.0% year-over-year to 34.22% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 21.63% (down 2253.0% YoY) and the FY2025 annual result came in at 13.9%, down 1069.0% from the prior year.
• Net Margin declined to 34.22% in Q4 2025, from 5.0% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 50.86% in Q1 2024 to a low of 355.34% in Q1 2023.
• A 3-year average of 64.92% and a median of 29.94% in 2023 frame the typical range for Net Margin.
• Annual changes were most pronounced in 2024 — Net Margin surged 40619 bps — and 2025, when it tumbled 6416 bps.
• Tracing FENC's Net Margin over 3 years: stood at 26.89% in 2023, then jumped by 41 bps to 15.81% in 2024, then tumbled by 116 bps to 34.22% in 2025.
• The last three Net Margin figures came in at 34.22% (Q4 2025), 5.0% (Q3 2025), and 32.69% (Q2 2025), per Business Quant data.